Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis

Authors:

Abstract
The pivotal U.S. CoreValve High Risk Study by Adams et al. (May 8 issue)1 clearly showed that the benefits of transcatheter aortic-valve replacement (TAVR) with the use of CoreValve (Medtronic) outweigh the harms, as compared with surgical aortic-valve replacement, in patients with severe aortic stenosis. The noninferiority criterion for the primary end point of mortality was met in the as-treated and intention-to-treat populations, and the result was robust with regard to missing data. However, the case for superiority was less clear. I estimate that only a few excess events in the TAVR group would have rendered the result nonsignificant; the one-sided P value calculated by means of the chi-square test is 0.053 for one excess event and 0.063 for two excess events.

This publication has 3 references indexed in Scilit: